Problems WIth ADHD Drugs Continue
Last month the FDA directed all manufacturers of drugs approved for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) to develop Patient Medication Guides alerting patients to the potential risks of the drugs. In addtion to past risks, the Medication Guides are intended to warn of possible cardiovascular events and adverse psychiatric events.
It seems that we are routinely hearing about new concerns and warnings regarding ADHD drugs. Considering the millions of people that take these drugs, the FDA should take a hard look at the benefits vs. risks of each drug in the class.
The full FDA news release may be found here.